Ch 3: VALIANT Results on the Longer-Term Impact of Empaveli @checkrare
Ch 3: VALIANT Results on the Longer-Term Impact of Empaveli  @checkrare
Uploaded November 2026 | Updated November 2026, 4 days ago
Bradley Dixon, MD, a pediatric nephrologist, and Chief of Pediatric Nephrology, Children’s Hospital of Colorado, and Professor of Pediatrics, University of Colorado School of Medicine, discusses the long-term impact of Empaveli on patients with C3G.
Ch 3: VALIANT Results on the Longer-Term Impact of EmpaveliFDA Approves New Therapies for MPS IIIA and SMA | The CheckRare Brief Ep 8Fabry Disease: Patients Real-World Problems and How to Manage ThemA Family’s Journey with Prader-Willi SyndromeCongenital Hyperinsulinism Diagnosis and ManagementResults from the CALIBRATE Clinical Trial in Patients With Autosomal Dominant Hypocalcemia Type 1Decoding Delays, Connecting the Care: The Challenge of Diagnosing Rare Endocrine DisordersRare Endocrine Exchange: Diagnosing Rare Endocrine DisordersAntiphospholipid Syndrome and PregnantASCO 2026: MajesTEC-9 Clinical Trial ResultsTaletrectinib for ROS1-Positive Non-Small Cell Lung CancerBreakthrough Therapy Designation to Cimzia for Antiphospholipid Syndrome
CheckRare |

Ch 3: VALIANT Results on the Longer-Term Impact of Empaveli

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER